Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.

Oncotarget · 2017 · PMC5354847 · PMID 27965460

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

a strong trendp < 0.08so close (0.05 < p ≤ 0.1)

To our surprise, depletion of KIT and ABL1 in combination did not lead to an increased effect when compared to depletion of KIT alone, but rather to a significantly attenuated reduction of cellular proliferation ( p < 0.02) and a strong trend towards a reduced induction of apoptosis ( p < 0.08).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.